Ipsen writes check worth up to €1B to acquire next-gen cancer biotech
Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy in a deal worth up to 1 billion euros (about $1.16 billion). The French pharma is…